Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its fourth quarter and full-year 2025 financial results conference call. Management also discussed commercial launch preparations for HCV and reviewed the company’s year-end cash position and spending outlook. […]

Amylyx Pharmaceuticals (NASDAQ:AMLX) executives told investors the company entered 2026 with a focus on advancing avexitide toward what could become the first FDA-approved therapy for post-bariatric hypoglycemia (PBH), while continuing early-stage work across its pipeline and maintaining a cash runway management said extends into 2028. Avexitide’s pivotal trial: timeline, endpoint, and powering assumptions Co-CEO Justin […]

uniQure (NASDAQ:QURE) used its fourth-quarter and full-year 2025 earnings call to outline next steps for its lead Huntington’s disease gene therapy program AMT-130 after receiving additional regulatory feedback from the U.S. Food and Drug Administration, while also providing updates across its Fabry disease and epilepsy pipelines and reviewing year-end financial results. AMT-130: company highlights three-year […]

Rhythm Pharmaceuticals (NASDAQ:RYTM) executives highlighted continued commercial growth for IMCIVREE and outlined a series of near-term regulatory and clinical milestones during the company’s fourth quarter and fiscal year 2025 earnings call. Management also provided updated longer-term development plans for next-generation MC4R agonists, including additional data from the Phase 2 bivamelagon program in hypothalamic obesity (HO). […]

Zai Lab (NASDAQ:ZLAB) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline progress toward a more globally oriented pipeline while emphasizing that the company’s China commercial business remains a key source of stability and funding for research and development. Founder, CEO, and Chairperson Dr. Samantha Du said Zai Lab is “building a […]

Beam Therapeutics (NASDAQ:BEAM) outlined a new liver-targeted development program for phenylketonuria (PKU) and announced a large, non-dilutive financing tied to its sickle cell disease launch plans during its fourth-quarter and full-year 2025 results call. New PKU program: BEAM-304 Chief Executive Officer John Evans said the company is expanding its liver franchise with BEAM-304, an in […]

Beam Therapeutics (NASDAQ:BEAM) outlined a new liver-targeted development program for phenylketonuria (PKU) and announced a large, non-dilutive financing tied to its sickle cell disease launch plans during its fourth-quarter and full-year 2025 results call. New PKU program: BEAM-304 Chief Executive Officer John Evans said the company is expanding its liver franchise with BEAM-304, an in […]